Fumie Ihara1,2, Daiju Sakurai1, Atsushi Horinaka1, Yuji Makita1, Akira Fujikawa1, Toshioki Sakurai1, Kazuki Yamasaki1, Naoki Kunii1, Shinichiro Motohashi2, Toshinori Nakayama3, Yoshitaka Okamoto4. 1. Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. 2. Department of Medical Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan. 3. Department of Immunology, Graduate School of Medicine, Chiba University, Chiba, Japan. 4. Department of Otorhinolaryngology, Head and Neck Surgery, Graduate School of Medicine, Chiba University, 1-8-1 Inohana, Chuo-ku, Chiba, 260-8670, Japan. yokamoto@faculty.chiba-u.jp.
Abstract
BACKGROUND: Although regulatory T cells (Tregs) are thought to play an important role in immune suppression, their clinical significance in head and neck squamous cell carcinoma (HNSCC) is unclear. A recent study reported Tregs could be divided into functional subsets based on the expression of CD45RA and Foxp3. METHOD: The frequency of circulating Treg subsets was analyzed in patients with HNSCC and compared with the frequency in patients with benign tumors. The association of Treg subsets with the frequency of lymphocyte subsets, status of progression, clinical course, and prognosis were also examined. RESULTS: The frequency of CD4+Foxp3+ Tregs was comparable between HNSCC patients and age-matched benign tumor patients; however, CD45RA-Foxp3high Tregs were significantly increased in HNSCC patients, in particular those with advanced stage tumors. The high frequency of CD45RA-Foxp3high Tregs correlated with a poor prognosis and the low frequency of CD45RA-Foxp3high Tregs before treatment showed a better clinical outcome, even in patients with advanced stage tumors. CD45RA-Foxp3high Treg numbers were decreased after intensive treatments; however, Treg numbers recovered in the early stages of recurrent cases, even before the clinical manifestation. CONCLUSION: CD45RA-Foxp3high Tregs are associated with the clinical course of HNSCC and might be a new target for treatment and an early marker of tumor recurrence in HNSCC patients.
BACKGROUND: Although regulatory T cells (Tregs) are thought to play an important role in immune suppression, their clinical significance in head and neck squamous cell carcinoma (HNSCC) is unclear. A recent study reported Tregs could be divided into functional subsets based on the expression of CD45RA and Foxp3. METHOD: The frequency of circulating Treg subsets was analyzed in patients with HNSCC and compared with the frequency in patients with benign tumors. The association of Treg subsets with the frequency of lymphocyte subsets, status of progression, clinical course, and prognosis were also examined. RESULTS: The frequency of CD4+Foxp3+ Tregs was comparable between HNSCC patients and age-matched benign tumorpatients; however, CD45RA-Foxp3high Tregs were significantly increased in HNSCC patients, in particular those with advanced stage tumors. The high frequency of CD45RA-Foxp3high Tregs correlated with a poor prognosis and the low frequency of CD45RA-Foxp3high Tregs before treatment showed a better clinical outcome, even in patients with advanced stage tumors. CD45RA-Foxp3high Treg numbers were decreased after intensive treatments; however, Treg numbers recovered in the early stages of recurrent cases, even before the clinical manifestation. CONCLUSION: CD45RA-Foxp3high Tregs are associated with the clinical course of HNSCC and might be a new target for treatment and an early marker of tumor recurrence in HNSCC patients.
Entities:
Keywords:
Biomarker; Head and neck cancer; Immunotherapy; Prognosis; Regulatory T cell
Authors: Bianca Cioni; Ekaterina S Jordanova; Erik Hooijberg; Rianne van der Linden; Renee X de Menezes; Katherine Tan; Stefan Willems; Joris B W Elbers; Annegien Broeks; Andries M Bergman; Charlotte L Zuur; Jan Paul de Boer Journal: Head Neck Date: 2018-12-14 Impact factor: 3.147
Authors: Ayman Oweida; Mohammad K Hararah; Andy Phan; David Binder; Shilpa Bhatia; Shelby Lennon; Sanjana Bukkapatnam; Benjamin Van Court; Nomin Uyanga; Laurel Darragh; Hyun Min Kim; David Raben; Aik Choon Tan; Lynn Heasley; Eric Clambey; Raphael Nemenoff; Sana D Karam Journal: Clin Cancer Res Date: 2018-07-24 Impact factor: 12.531
Authors: Christopher A Chuckran; Anthony R Cillo; Jessica Moskovitz; Abigail Overacre-Delgoffe; Ashwin S Somasundaram; Feng Shan; Grant C Magnon; Sheryl R Kunning; Irina Abecassis; Amer H Zureikat; James Luketich; Arjun Pennathur; John Sembrat; Mauricio Rojas; Daniel T Merrick; Sarah E Taylor; Brian Orr; Francesmary Modugno; Ron Buckanovich; Robert E Schoen; Seungwon Kim; Umamaheswar Duvvuri; Herbert Zeh; Robert Edwards; John M Kirkwood; Lan Coffman; Robert L Ferris; Tullia C Bruno; Dario A A Vignali Journal: Sci Transl Med Date: 2021-12-08 Impact factor: 19.319